Duiker, Evelien W <br/><br/>
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2009 
 - 2048-57 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-08-1535  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cisplatin--pharmacology<br/>Female<br/>Humans<br/>Luminescent Measurements<br/>Mice<br/>Ovarian Neoplasms--drug therapy<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--metabolism<br/>Recombinant Proteins--pharmacology<br/>TNF-Related Apoptosis-Inducing Ligand--pharmacokinetics<br/>Tissue Distribution<br/>Xenograft Model Antitumor Assays